Interaction of ionizing radiation with topotecan in two human tumor cell lines

Renato Marchesini, Ambrogio Colombo, Claudia Caserini, Paola Perego, Rosanna Supino, Giovanni Capranico, Marco Tronconi, Franco Zunino

Research output: Contribution to journalArticle

Abstract

The effect of topotecan, a topoisomerase I inhibitor, on ionizing radiation-induced cytotoxicity was studied in 2 human tumor cell lines characterized by a different expression of the target enzyme. The cytotoxicity of topotecan alone or in combination with radiation was assessed in exponentially growing non-small-cell lung cancer (H460) and glioblastoma (GEM) cells using the colony-forming assay. An isobologram method was used to evaluate the treatment interaction. An apparent supra-additive effect in cell killing following drug-radiation-combined treatment was observed only in GEM cells exposed to topotecan for 24 hr. In the case of H460 cells, interaction varied from a strong infra-additive effect at low radiation doses to a slight supra-additive effect when cells were exposed to radiation doses greater than 3 Gy. Northern blot analysis indicated that topoisomerase 1 expression in H460 cells was 8-fold higher than that of GEM cells. Although the H460 cell line exhibited an increased sensitivity to topotecan, only in the GEM cell line (which expressed a lower level of topoisomerase I did the drug potentiate the radiation cytotoxicity. The observation that the radiosensitization by topotecan was related to topoisomerase I level is consistent with a putative role of the enzyme in processes involved in the repair of radiation damage. It is conceivable that the modulation of enzyme function results in an effective reduction of cellular capability for repair of radiation damage only if the enzyme is not over-expressed. Although a precise role of topoisomerase I in the cellular response to ionizing radiations (in particular, in DNA repair) remains to be documented, such results suggest the potential interest of topoisomerase I inhibitors in combination with radiation therapy for tumors expressing low topoisomerase I levels.

Original languageEnglish
Pages (from-to)342-346
Number of pages5
JournalInternational Journal of Cancer
Volume66
Issue number3
DOIs
Publication statusPublished - May 3 1996

Fingerprint

Topotecan
Ionizing Radiation
Tumor Cell Line
Type I DNA Topoisomerase
Radiation
Topoisomerase I Inhibitors
Enzymes
Cell Line
Glioblastoma
Non-Small Cell Lung Carcinoma
Cell Communication
DNA Repair
Pharmaceutical Preparations
Northern Blotting
Radiotherapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Interaction of ionizing radiation with topotecan in two human tumor cell lines. / Marchesini, Renato; Colombo, Ambrogio; Caserini, Claudia; Perego, Paola; Supino, Rosanna; Capranico, Giovanni; Tronconi, Marco; Zunino, Franco.

In: International Journal of Cancer, Vol. 66, No. 3, 03.05.1996, p. 342-346.

Research output: Contribution to journalArticle

Marchesini, Renato ; Colombo, Ambrogio ; Caserini, Claudia ; Perego, Paola ; Supino, Rosanna ; Capranico, Giovanni ; Tronconi, Marco ; Zunino, Franco. / Interaction of ionizing radiation with topotecan in two human tumor cell lines. In: International Journal of Cancer. 1996 ; Vol. 66, No. 3. pp. 342-346.
@article{c0ee9552e02a4ad392a6a75e0363e616,
title = "Interaction of ionizing radiation with topotecan in two human tumor cell lines",
abstract = "The effect of topotecan, a topoisomerase I inhibitor, on ionizing radiation-induced cytotoxicity was studied in 2 human tumor cell lines characterized by a different expression of the target enzyme. The cytotoxicity of topotecan alone or in combination with radiation was assessed in exponentially growing non-small-cell lung cancer (H460) and glioblastoma (GEM) cells using the colony-forming assay. An isobologram method was used to evaluate the treatment interaction. An apparent supra-additive effect in cell killing following drug-radiation-combined treatment was observed only in GEM cells exposed to topotecan for 24 hr. In the case of H460 cells, interaction varied from a strong infra-additive effect at low radiation doses to a slight supra-additive effect when cells were exposed to radiation doses greater than 3 Gy. Northern blot analysis indicated that topoisomerase 1 expression in H460 cells was 8-fold higher than that of GEM cells. Although the H460 cell line exhibited an increased sensitivity to topotecan, only in the GEM cell line (which expressed a lower level of topoisomerase I did the drug potentiate the radiation cytotoxicity. The observation that the radiosensitization by topotecan was related to topoisomerase I level is consistent with a putative role of the enzyme in processes involved in the repair of radiation damage. It is conceivable that the modulation of enzyme function results in an effective reduction of cellular capability for repair of radiation damage only if the enzyme is not over-expressed. Although a precise role of topoisomerase I in the cellular response to ionizing radiations (in particular, in DNA repair) remains to be documented, such results suggest the potential interest of topoisomerase I inhibitors in combination with radiation therapy for tumors expressing low topoisomerase I levels.",
author = "Renato Marchesini and Ambrogio Colombo and Claudia Caserini and Paola Perego and Rosanna Supino and Giovanni Capranico and Marco Tronconi and Franco Zunino",
year = "1996",
month = "5",
day = "3",
doi = "10.1002/(SICI)1097-0215(19960503)66:3<342::AID-IJC13>3.0.CO;2-D",
language = "English",
volume = "66",
pages = "342--346",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Interaction of ionizing radiation with topotecan in two human tumor cell lines

AU - Marchesini, Renato

AU - Colombo, Ambrogio

AU - Caserini, Claudia

AU - Perego, Paola

AU - Supino, Rosanna

AU - Capranico, Giovanni

AU - Tronconi, Marco

AU - Zunino, Franco

PY - 1996/5/3

Y1 - 1996/5/3

N2 - The effect of topotecan, a topoisomerase I inhibitor, on ionizing radiation-induced cytotoxicity was studied in 2 human tumor cell lines characterized by a different expression of the target enzyme. The cytotoxicity of topotecan alone or in combination with radiation was assessed in exponentially growing non-small-cell lung cancer (H460) and glioblastoma (GEM) cells using the colony-forming assay. An isobologram method was used to evaluate the treatment interaction. An apparent supra-additive effect in cell killing following drug-radiation-combined treatment was observed only in GEM cells exposed to topotecan for 24 hr. In the case of H460 cells, interaction varied from a strong infra-additive effect at low radiation doses to a slight supra-additive effect when cells were exposed to radiation doses greater than 3 Gy. Northern blot analysis indicated that topoisomerase 1 expression in H460 cells was 8-fold higher than that of GEM cells. Although the H460 cell line exhibited an increased sensitivity to topotecan, only in the GEM cell line (which expressed a lower level of topoisomerase I did the drug potentiate the radiation cytotoxicity. The observation that the radiosensitization by topotecan was related to topoisomerase I level is consistent with a putative role of the enzyme in processes involved in the repair of radiation damage. It is conceivable that the modulation of enzyme function results in an effective reduction of cellular capability for repair of radiation damage only if the enzyme is not over-expressed. Although a precise role of topoisomerase I in the cellular response to ionizing radiations (in particular, in DNA repair) remains to be documented, such results suggest the potential interest of topoisomerase I inhibitors in combination with radiation therapy for tumors expressing low topoisomerase I levels.

AB - The effect of topotecan, a topoisomerase I inhibitor, on ionizing radiation-induced cytotoxicity was studied in 2 human tumor cell lines characterized by a different expression of the target enzyme. The cytotoxicity of topotecan alone or in combination with radiation was assessed in exponentially growing non-small-cell lung cancer (H460) and glioblastoma (GEM) cells using the colony-forming assay. An isobologram method was used to evaluate the treatment interaction. An apparent supra-additive effect in cell killing following drug-radiation-combined treatment was observed only in GEM cells exposed to topotecan for 24 hr. In the case of H460 cells, interaction varied from a strong infra-additive effect at low radiation doses to a slight supra-additive effect when cells were exposed to radiation doses greater than 3 Gy. Northern blot analysis indicated that topoisomerase 1 expression in H460 cells was 8-fold higher than that of GEM cells. Although the H460 cell line exhibited an increased sensitivity to topotecan, only in the GEM cell line (which expressed a lower level of topoisomerase I did the drug potentiate the radiation cytotoxicity. The observation that the radiosensitization by topotecan was related to topoisomerase I level is consistent with a putative role of the enzyme in processes involved in the repair of radiation damage. It is conceivable that the modulation of enzyme function results in an effective reduction of cellular capability for repair of radiation damage only if the enzyme is not over-expressed. Although a precise role of topoisomerase I in the cellular response to ionizing radiations (in particular, in DNA repair) remains to be documented, such results suggest the potential interest of topoisomerase I inhibitors in combination with radiation therapy for tumors expressing low topoisomerase I levels.

UR - http://www.scopus.com/inward/record.url?scp=0029884474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029884474&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19960503)66:3<342::AID-IJC13>3.0.CO;2-D

DO - 10.1002/(SICI)1097-0215(19960503)66:3<342::AID-IJC13>3.0.CO;2-D

M3 - Article

C2 - 8621255

AN - SCOPUS:0029884474

VL - 66

SP - 342

EP - 346

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -